- Record: found
- Abstract: not found
- Article: not found
Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma
John K. Lin
1
,
2 ,
Lori S. Muffly
3 ,
Michael A. Spinner
3 ,
James I. Barnes
1
,
2 ,
Douglas K. Owens
1
,
2 ,
Jeremy D. Goldhaber-Fiebert
2
June 03 2019
June 03 2019
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d16701111e115">Two anti-CD19 chimeric antigen receptor T-cell
(CAR-T) therapies are approved for
diffuse large B-cell lymphoma, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel;
each costs $373,000. We evaluated their cost effectiveness.
</p>